PacBio will host its Q3 2025 earnings call on November 5, 2025, at 4:30 pm ET.
Quiver AI Summary
PacBio has announced that it will host a conference call to discuss its third quarter 2025 financial results on November 5, 2025, at 4:30 pm Eastern Time. The call will be available via webcast on the company's investor relations website, and participants can also join by phone. The press release emphasizes PacBio's role as a leading life science technology company, specializing in advanced sequencing solutions that aid in various research applications, including genomics and oncology. For further information, investors and media can contact specified representatives via email.
Potential Positives
- Announcement of the quarterly conference call indicates transparency and commitment to keeping investors informed about financial performance.
- The scheduled call allows for direct interaction with company leadership, enhancing investor relations.
- The webcast format provides accessible information to a wider audience, including those unable to attend in person.
- PacBio's emphasis on advanced sequencing solutions highlights its leadership in the life science technology sector and ongoing innovation in genetic research.
Potential Negatives
- Timing of the quarterly conference call occurring after the end of the quarter may suggest potential delays in financial reporting or performance evaluation.
FAQ
When is PacBio's Q3 2025 earnings call scheduled?
PacBio's Q3 2025 earnings call is scheduled for Wednesday, November 5, 2025, at 4:30 pm ET.
How can I access the PacBio earnings call?
You can access the call via webcast on PacBio’s investor website at https://investor.pacificbiosciences.com/.
What is PacBio known for?
PacBio is known for designing and manufacturing advanced sequencing solutions for life sciences research.
What technology does PacBio offer?
PacBio offers HiFi long-read sequencing technology for various research applications, including oncology and microbiology.
Is PacBio's technology suitable for diagnostic procedures?
No, PacBio products are for Research Use Only and not intended for diagnostic procedures.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PACB Insider Trading Activity
$PACB insiders have traded $PACB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PACB stock by insiders over the last 6 months:
- OENE MARK VAN (See Remarks) sold 26,836 shares for an estimated $35,181
- MICHELE FARMER (See Remarks) sold 5,195 shares for an estimated $5,200
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PACB Hedge Fund Activity
We have seen 76 institutional investors add shares of $PACB stock to their portfolio, and 118 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EDMOND DE ROTHSCHILD HOLDING S.A. removed 8,488,980 shares (-38.8%) from their portfolio in Q2 2025, for an estimated $10,526,335
- MADRONE ADVISORS, LLC removed 6,629,699 shares (-28.3%) from their portfolio in Q2 2025, for an estimated $8,220,826
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 4,881,313 shares (-99.9%) from their portfolio in Q2 2025, for an estimated $6,052,828
- JACKSON SQUARE PARTNERS, LLC removed 2,767,258 shares (-83.3%) from their portfolio in Q2 2025, for an estimated $3,431,399
- MORGAN STANLEY removed 2,539,962 shares (-75.3%) from their portfolio in Q2 2025, for an estimated $3,149,552
- POINT72 (DIFC) LTD added 2,459,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,049,160
- GOLDMAN SACHS GROUP INC removed 1,379,742 shares (-74.0%) from their portfolio in Q2 2025, for an estimated $1,710,880
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PACB Analyst Ratings
Wall Street analysts have issued reports on $PACB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 05/15/2025
To track analyst ratings and price targets for $PACB, check out Quiver Quantitative's $PACB forecast page.
$PACB Price Targets
Multiple analysts have issued price targets for $PACB recently. We have seen 3 analysts offer price targets for $PACB in the last 6 months, with a median target of $1.5.
Here are some recent targets:
- David Westenberg from Piper Sandler set a target price of $1.5 on 08/11/2025
- Luke Sergott from Barclays set a target price of $1.5 on 06/25/2025
- Mason Carrico from Stephens & Co. set a target price of $1.8 on 05/15/2025
Full Release
MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time.
The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/ .
Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)
Listen live via internet or replay:
https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459
If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the “PacBio Q3 Earnings Call.”
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Jim Gibson
[email protected]
Media:
[email protected]
